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ABSTRACT 
Purpose: We conducted a retrospective, nationwide analysis to describe the clinical outcome of 
adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) 
undergoing allogeneic hematopoietic stem cell transplantation (HSCT) after being treated with a 
TKI based therapy. 
Patients and results: A total of 441 patients were included in the study. The median age at HSCT 
was 44 (range: 18-70). All 441 patients (100%) received TKI before HSCT (performed between 
2005-2016). Of these patients, 404 (92%) were in cytologic complete remission (CR) while 37 (8%) 
had an active disease at the time of HSCT. Molecularly Measurable Residual Disease (MRD) was 
negative in 147 patients (36%) at the time of HSCT. The donor was unrelated in 46% of cases. The 
prevalent source of stem cells was peripheral blood (70%). The conditioning regimen was 
myeloablative in 82% of cases (TBI-based in 50%) and included ATG in 51% of cases. With a 
median follow-up after HSCT of 39.4 months (range: 1-145), the probability of Overall Survival 
(OS) at 1, 2 and 5 years was 69.6%, 61.1%, and 50.3%, respectively, with a median OS of 62 
months. Progression Free Survival (PFS) at 1, 2 and 5 years was 60.2%, 52.1% and 43.7%, 
respectively. OS and PFS were significantly better in patients with CR and MRD-negativity at the 
time of transplant compared to patients with CR but MRD-positive (50% OS not reached vs. 36 
months, P=0,015; 50% PFS not reached vs. 26 months, P=0.003). The cumulative incidence of 
relapse (CIR) at 5 years was significantly lower in patients with CR and MRD-negativity (19.5% 
vs. 35.4%, P=0.001). The non relapse mortality (NRM) after 1, 2, and 5 years was 19.1% (95%CI: 
15.5-22.9), 20.7% (95%CI: 17-24.7), and 24.1% (95%CI: 20-28.5), respectively. The subgroup of 
patients with MRD-negative both at HSCT and at 3rd month after HSCT had a better outcome (5 
year OS 70%). Conversely, the 37 patients who underwent HSCT with active Ph+ALL had a 
median OS and PFS of 7 and 5 months, respectively. 
Conclusions: The median OS of all patients with Ph+ALL, treated with TKI based therapy and 
allografted in recent years at the GITMO Centers, is 62 months. The outcome of Ph+ALL patients 
undergoing HSCT after TKI therapy has improved (with a 2 yrs NRM of 20,7%), particularly for 
younger patients and those achieving a molecular remission before transplant (50% OS and PFS not 
reached). HSCT remains a standard of care consolidation treatment for Ph+ALL and only 
prospective randomized trials can suggest a survival benefit of non transplant based treatment 
strategies. 
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INTRODUCTION 
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) accounts for 
approximately 25% of ALL cases in adults. Historically, it is characterized by a very unfavorable 
prognosis, with an overall survival (OS) rate of less than 20% after 5 years according to the major 
epidemiological studies available.
1,2
 For many years, the treatment of Ph+ALL was based on 
intensive chemotherapy regimens followed by allogeneic stem cell transplantation (HSCT), which 
is still the only established procedure with curative intent for this disease.
2-4
 Over the last decade, 
Tyrosine Kinase Inhibitors (TKI), mainly imatinib and dasatinib and more recently ponatinib, were 
gradually incorporated into both chemotherapy-based and chemotherapy-free induction regimens.
2, 
5-15
 The outcome improvement achieved by TKI based treatments has challenged the concept that a 
transplant based consolidation of remission is always mandatory.
16-18
 In light of these recent 
treatment changes, an extensive activity of data reviewing has been done by several groups in order 
to update the results of HSCT in Ph+ALL in the era of TKIs paying attention to both pre and post-
transplant phases.
2,12,14,19
 To address this need, the European Society for Blood and Marrow 
Transplantation (EBMT) and the Japan Society for Hematopoietic Cell Transplantation (JSHCT) 
recently reviewed the outcome of Ph+ALL undergoing HSCT in their centers in the last decades 
(from 2000 to 2010 for EBMT and from 1990 to 2000 for the JSHCT).
14,19
 The study reported 
herein is the most recent registry study that analyze the experience of the Italian Blood and Marrow 
Transplantation Society (GITMO) regarding the outcome of HSCT (performed between 2005 and 
2016) for Ph+ALL patients in the era of TKI based therapy. 
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MATERIALS and METHODS 
a) Study design.  
This was a retrospective nationwide analysis based on registry data collected by GITMO. Inclusion 
criteria were: 1) diagnosis of Ph+ALL; age > 18 years at transplant; 2) patients receiving first 
allogeneic HSCT from any donor (HLA-identical sibling donor (MSD), unrelated donor (UD) or 
alternative donor (haploidentical or cord blood) between 2005 and 2016 in a GITMO center; 3) 
TKI-based treatment prior to HSCT; 4) patients with available pre transplant MRD status, as well as 
complete clinical data and outcome. Data were extracted from the GITMO Registry (PROMISE 
Registry).  
The endpoints of the study were: Overall Survival (OS), Progression-free Survival (PFS), 
cumulative incidence of Relapse (CIR), Non-relapse Mortality (NRM), cumulative incidence of 
extensive chronic GVHD (cGVHD), rate of MRD negativity and the rate of CR before and after 
transplant.  
Data were centrally reviewed following the initial collection and queries were sent to the relevant 
parties for any conflicting and/or missing information.  
All patients included in the registry signed an informed consent form. The study was conducted in 
compliance with current national and European legislation on clinical trials, in accordance with the 
Helsinki Declaration and the principles of good clinical practice (GCP). This study was approved 
by the GITMO board and by the institutional review board of the coordinating center (Hematology–
University of Udine), and from institutional review board of all participating centers.  
A list of Institutions reporting the data included in the current study is available in a Supplementary 
file. 
b) Definitions.  
Complete cytologic remission (CR) was defined as the absence of circulating blasts, less than 5% 
bone marrow (BM) blasts and a platelet count of 100x10
9
/L or higher. Relapse was defined as the 
reappearance of >5% leukemic cells in bone marrow aspirates or extramedullary leukemia in 
patients with previously documented CR.  
Cytogenetic analysis was performed using the G-banding technique. Complete Cytogenetic 
Remission (Cytogenetic CR) was defined as having obtained a normal cytogenetic result in at least 
20 metaphases.  
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BCR-ABL transcripts were detected by real-time quantitative polymerase chain reaction (PCR) 
according to validated methods.
21,22
 Minimal Residual Disease (MRD) negativity was defined as 
undetectable BCR-ABL mRNA transcripts by real-time qPCR. Investigators were asked to provide 
MRD data at the time of transplant (within 30 days prior to procedure) and after HSCT.  
Acute graft versus host disease (aGVHD) was computed when graded > 1 based on standard criteria 
and requiring therapy. Chronic GVHD (cGVHD) was classified as none, limited or extensive 
(EcGVHD) according to Seattle criteria.
23 
The aGVHD persisting or progressing after day 100 was 
scored as cGVHD.  
The timing of HSCT, the conditioning regimen, GVHD prophylaxis and post HSCT timing of 
BCR-ABL monitoring were defined by each Institution according to their active protocols.  
c) Statistical analysis.  
To compare baseline characteristics or outcome measures among subgroups, we used the Chi-
square or Fisher’s exact test for categorical variables, the Student’s t-test for normally distributed 
variables and the Mann-Whitney or Kruskal-Wallis test for non-normally distributed variables. 
Median follow-up time was calculated among survivors. 
Overall survival (OS) was defined as the time from HSCT to death, regardless of the cause. PFS 
was considered to be survival following HSCT with no evidence of relapse or progression. Death 
from any cause was considered as an event for OS, whereas relapse/progression and death from any 
cause were considered as events for PFS. OS and PFS were computed using the Kaplan-Meier 
method. Univariate and multivariate analyses were performed using the Cox proportional hazard 
method. 
The cumulative incidence method was used for computing CIR, NRM and extensive cGvHD in a 
competing risks setting. CIR was estimated by considering relapse as the event of interest and death 
without relapse as a competing event. NRM was defined as death without evidence of relapse or 
progression, with relapse as a competing event.  
Extensive cGVHD was estimated by considering the occurrence of extensive cGVHD as an event of 
interest and death without cGVHD as a competing risk, with leukemia relapse treated as a 
competing risk if it occurred without prior GVHD. 
Predictive analyses for extensive cGVHD, CIR and NRM were based on the proportional hazard 
model for subdistribution of competing risk. Univariate and multivariate analyses were then 
performed using Gray's test and the proportional subdistribution hazard regression model developed 
by Fine and Gray. In general, a stepwise backwards procedure was used to construct a set of 
independent predictors for each endpoint. All predictors with a P-value less than 0.20 were 
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considered, and then sequentially removed if the P-value in the multiple model was above 0.05. All 
tests were 2-sided. The type I error rate was fixed at 0.05. However, the whole procedure and the 
final model accounted for manual adjustments, i.e. exclusion of variables with partial overlapping 
information (collinearity) or categorization of continuous or non-dichotomous categorical variables 
according to clinical relevance. Factors considered were: patient sex, disease characteristics at 
diagnosis (presence of hyperleukocytosis, defined as >30x10
9
 WBC/L; additional cytogenetic 
abnormalities beyond t(9:22)), pre-transplant therapeutic strategy (use of TKI + steroids vs. TKI + 
chemotherapy), the patient’s age at transplantation, donor sex, disease status at time of 
transplantation (1
st
 CR vs. 2
nd
 and subsequent CR vs. advanced disease), donor type (matched 
sibling vs. unrelated donor vs. alternative donor-i.e. haploidentical or cord blood), source of stem 
cells (peripheral blood vs. bone marrow vs. cord blood), year of transplantation, time from 
diagnosis to transplant, CMV serostatus of recipient and donor, hematopoietic cell transplantation 
specific comorbidity index (HCT-CI) at transplant, Karnofsky performance status (KPS) at 
transplant (≥ 90 vs. <90), molecular remission status at transplant, type of conditioning (reduced-
intensity conditioning-RIC vs. myeloablative-MAC) and use of antithymocyte globulin (ATG) and 
total body irradiation (TBI) in the conditioning regimen. Patient age and year of transplantation 
were analyzed as continuous variables. In order to evaluate the impact of the molecular response 
measured in the first 3 months after transplant on survival endpoints, a landmark analysis was 
applied for OS and PFS using a landmark day 90 after HSCT. Analyses were performed using Stata 
12.0 (Statacorp, College Station, Texas). 
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RESULTS 
a) Patients and Ph+ALL status at HSCT. 
A total of 441 patients were included in the study. The main clinical findings are reported in 
TABLE 1. The median age at transplantation was 44 (range: 18-70). Additional karyotype 
abnormalities were reported in 30% of evaluable cases (124/416). All 441 patients (100%) received 
TKI before transplant: 80 (18%) had received TKI + steroids while 361 (82%) had received TKI + 
chemotherapy. The patients in this second group, compared to patients treated with TKI + steroids 
alone, had a significantly higher leukocyte count at ALL diagnosis (P=0.001). The median interval 
between the diagnosis of Ph+ALL and HSCT was 7.67 months (range: 2.3-78.8) without significant 
differences between the 2 pre HSCT treatment groups (P=0.83). Patients who received HSCT in 1
st
 
CR had a shorter interval between diagnosis to HSCT (median: 6.83 months) than patients who 
received transplants in >1
st
 CR (median: 11.43 months) and patients with active disease at HSCT 
(median: 10.03 months, p-value for any difference among groups <0,001). 
Of these 441 patients, 404 (92%) were in complete cytologic remission at the time of HSCT, while 
37 (8%) had an active disease. In detail, of the 404 patients in CR at the time of HSCT, 337 patients 
(83%) were in 1
st
 CR, while 67 patients (17%) were in 2
nd 
or subsequent CR. A significantly higher 
percentage of patients transplanted in >1
st
 CR had been treated with CHT+TKI before HSCT (20% 
vs. 4%, P<0,001).  
There were 147/404 patients in CR and MRD-negative (36%) at the time of  HSCT. A significantly 
higher proportion of patients treated with TKI + steroids were MRD-negative at the time of 
transplantation (40/76-53%) compared to patients treated with TKI + CHT (107/328-33%) 
(P=0.001). 
b) Transplantation characteristics and outcome.  
Patients received a variety of HSCT preparative regimens based on existing available protocols at 
time of treatment. Only 27% (118/441) of HSCT procedures were performed from 2005 to 2010, 
while 323/441 (73%) were performed from 2011 to 2016. The main characteristics of the HSCT are 
reported in TABLE 2. The donor was unrelated in 46% of cases and the prevalent source of stem 
cells was peripheral blood-PB (70%). The conditioning regimen was myeloablative (MAC) in 82% 
of cases, and it was TBI-based in 50% of cases. ATG was used in 51% of cases. HCT-CI (available 
in 402 cases) ranged from 0-2 in 95% of patients. The median follow-up from the transplant was 
39.4 months (range of 1-145). 
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The probability of survival (OS) at 1, 2, 3 and 5 years from transplant was 69.6% (95%CI: 65-73.8), 
61.1% (95%CI: 56.2-65.7), 52.4% (95%CI: 46.8-57.1) and 50.3% (95%CI: 44.9.-55.4), 
respectively. The probability of Progression Free Survival (PFS) at 1, 2, 3 and 5 years was 60.2% 
(95%CI: 55.7-64.7), 52.1% (95%CI: 47.4-56.8), 45.1% (95%CI: 40.2-50) and 43.7% (95%CI: 38.7-
48.7), respectively.  
Among patient in CR, OS and PFS from transplant were significantly better in MRD-negative 
patients in comparison to those MRD-positive at the time of HSCT (P =0.015 for OS and P=0.003 
for PFS) (FIGURES 1A-D). The cumulative incidence of Relapse (CIR) at 2 and 5 years was 
27.9% (95% CI: 23.6-32.3) and 31.8% (95%CI: 27.1-36.5), respectively (FIGURE 2A). As 
expected, CIR was significantly lower in patients who were MRD-negative at the time of transplant 
compared to MRD-positive ones (Gray's test: SHR=0.47 [0.31–0.73], P=0.001) (FIGURE 2B). For 
the whole population of patients, the cumulative incidence of Non Relapse Mortality (NRM) at 1, 2, 
3 and 5 years was 19.1% (95%CI: 15.5-22.9), 20.7% (95%CI: 17-24.7), 24.1% (95%CI: 20-28.5) 
and 24.1% (95%CI: 20-28.5), respectively (FIGURE 2C).  
Acute GVHD requiring therapy was documented in 41% of cases and chronic GVHD requiring 
therapy was documented in 29%. The cumulative incidence of extensive cGVHD at 2 and 5 years 
from HSCT was 18.5% (95%CI: 14.9-22.4) and 19.8% (95%CI: 16-23.9), respectively (FIGURE 
2D). A total of 96/441 patients (22%) died of NRM. In detail, the causes of NRM were: GVHD in 
49/96 (51%), Infections in 33/96 (35%), PTT in 6/96 (6%), VOD in 1/96 (1%) and other causes in 
7/96 (7%).  
Of note, the 37 patients transplanted with active Ph+ALL had a very unfavorable post transplant 
outcome, with a median OS and PFS, from HSCT, of 7 and 5 months, respectively (FIGURES 1C 
and 1D). 
By univariate analysis (TABLE 3), many factors were associated with a favorable OS including: 
younger age, shorter interval between diagnosis and 1
st
 CR, early disease phase (1
st
 CR) at the time 
of transplantation, CR with MRD negativity at the time of transplantation, KPS >90%, a matched 
sibling or unrelated donor. The inclusion of TBI in the conditioning regime proved to be an 
additional favorable factor for PFS (TABLE 3).  
However, by multivariate analysis, as shown in TABLE 4, favorable predictive factors for OS and 
PFS remained: the use of a matched sibling or unrelated donor (P=0.001), being in 1st CR at the 
time of HSCT (P <0.001), a CR with MRD negativity at the time of transplantation,  a younger age 
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(P=0.013 for OS), a transplant performed in the most recent years (P=0.008) and the use of TKI and 
steroids prior to HSCT (P=0.008).  
Early disease phase, MRD negativity (P=0,008), lower age and more recent year of transplant were 
found to significantly predict also the incidence of Relapse. Of note no significant effect of donor 
type was seen while the use of TBI in the conditioning regimen (P=0.001) confirms its protective 
effect on relapse.  
The incidence of extensive chronic GVHD was significantly associated, in multivariate analysis, to 
HLA mismatching (alternative vs. UD and sibling; p=0.019), a female donor (P=0.01) and to the 
use of ATG (P=0.011) which was not associated instead to relapse risk. 
c) Impact of Disease Status at the 3rd month post HSCT on Outcome.  
421 patients were re-evaluated for MRD within the 3rd month from HSCT: 302/421 (72%) were 
MRD-negative. In particular, 177 (60%) of the 294 patients being MRD-positive or with active 
disease), were converted to MRD-negative within the 3rd month after HSCT (Supplemental Table 
1). 
A landmark analysis for OS and PFS showed that post transplant MRD negativity (at 3th month) 
had a significant favorable effect on OS and PFS post HSCT (landmark analysis for OS and PFS-
Supplemental Figure 1). However, roughly one third (100/302) of the 302 patients being MRD-
negative at the 3rd month after HSCT, molecularly relapsed thereafter, with a median time of 8 
months from transplant (range; 5-108). Unfortunately, in these cases of molecular relapse, a 
systematic evaluation of BCR-ABL mutations was not available, and therefore, these data are not 
evaluable in this study. 
d) TKIs post HSCT.  
TKI inhibitors were used in 40% of patients (178/441) in the post-transplant phase. In 74% of 
patients, TKIs were used as preemptive (53%-94/178) or prophylactic (21%-38/178) therapy, before 
cytological relapse. The strategy of TKIs use post HSCT (prophylaxis, preemptive, cytological 
recurrence) was very variable and not shared across the various centers. As expected, time for TKI 
start was earlier in the prophylaxis (median 102 days, range: 17-259) and pre-emptive (median 128 
days, range: 26-3233) groups, than in the relapse group (median 192 days, range 35-964). 
Of the 38 patients starting TKI post HSCT prophylactically, 13 (34%) had a molecular relapse after 
a median of 5.1 months (range: 0.9-47.6 months); of these, 5 had a concurrent and 3 developed later 
cytological relapse, while 5 never relapsed cytologically. Ninety-four patients started TKI after 
HSCT because of molecular relapse (pre-emptive treatment): 38 (40%) had a cytological relapse 
11 
 
after a median of 4.8 months (range 0.4-76.6 months) after start of TKI. In the group of patients 
treated pre-emptively (complete data available for 88 patients), the probability of survival free of 
cytological relapse or death (from start of TKI) was 64.7% (95%CI: 53.2%-74%), 57% (95%CI: 
45.1%-67.3%) and 55.1% (95%CI: 43%-65.6%) at 1, 2 and 5 year, respectively. 
Dasatinib was used after HSCT in 45.5% of cases (81/178), followed by imatinib in 35.3% (n=63), 
ponatinib in 16.3% (n=29), and nilotinib in 2.2% (n=4). When analyzed according to treatment 
strategy, dasatinib was still the most used TKI in the prophylactic (45%, n=17) and relapse groups 
(59%), whereas in the pre-emptive group imatinib was chosen in most cases (46%, n=43). As 
expected, ponatinib was mostly employed in the relapse group (n=14, 48% of 29 patients using 
ponatinib after HSCT). 
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DISCUSSION 
For many years, the curative options for Ph+ALL have been extremely limited, and 
chemotherapy followed by allogeneic HSCT has remained the primary standard of care of this 
disease. This approach allowed for a 5-year OS of 30-35%, whereas in patients not treated with 
HSCT, the expected 5-year OS was not greater than 10-15%.
11,17,24
 In recent years, the therapeutic 
scenario for adults with Ph+ALL has fortunately improved with the introduction of new drugs 
including the second and third generation inhibitors of tyrosine kinases (TKI), followed by anti-
CD19 and anti-CD22 monoclonal antibodies (Blinatumomab and Inotuzumab), and, more recently, 
the cell therapies with chimeric antigen receptor T cells (CAR-T cells).
25-31
 Some of these 
approaches are currently used in second line, but a shift  to the frontline setting is foreseeable, while 
use as maintenance therapy or MRD treatment represent other forthcoming options.
32
 The efficacy 
of TKIs in Ph+ALL treatment is without question considering their ability to obtain the CR with 
MRD negativity. Nevertheless, few data and studies are available today regarding the outcome of 
therapeutic programs including both TKI and HSCT and, to date, HSCT is still considered a 
standard of care to consolidate remission in Ph+ALL, even though recent results suggest that long 
lasting remission can be achieved and maintained even without transplantation.
10,25,33-35
 The 
retrospective nationwide analysis we present in this paper was undertaken to evaluate the clinical 
outcome of adult Ph+ALL patients who underwent HSCT in the TKIs-based therapy era. In keeping 
with previous reports, our results confirm the potential curative effect of HSCT in patients with 
Ph+ALL (TABLE 5).
14,19
 The long-term follow-up of this large analysis of patients receiving TKIs 
treatment prior to HSCT indicates that survival can be achieved close to 50%, a significant 
improvement compared to the pre-TKI era. A point of strength of this study is the inclusion of a 
large number of patients undergoing HSCT in a relatively short period of time (73% of HSCT 
included were performed from 2011 to 2016), as well as the long follow-up duration. In addition, all 
included patients received TKI before HSCT and had MRD evaluation before transplantatation 
consistently determined by quantitative polymerase chain reaction (RQ-PCR).   
As expected, for patients in CR, the main parameter that negatively affected outcomes was 
undergoing HSCT with measurable levels of MRD. Patients with negative MRD before HSCT had 
a 5-year OS and PFS significantly better compared with those with measurable levels of MRD. In 
keeping with other previous studies and registry data the improved clinical outcome was mainly due 
to a reduction in the cumulative incidence of relapse (CIR) in MRD negative patients.
14,19,36-38
 This 
observation emphasize the importance of achieving a robust remission before HSCT and with this 
aim  innovative treatments, such as second and third generation TKIs and anti-CD19 and anti-CD22 
monoclonal antibodies, should be strongly considered before transplantation. Not surprisingly, the 
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importance of achieving a complete molecular remission holds true also for patients who are 
excluded from HSCT as part of the front-line treatment and the long-term PFS that has been 
reported in some patients achieving MRD negative status without HSCT highlights the need of 
future prospective clinical trials comparing transplantation with the available innovative treatments 
based on TKIs and/or immunotherapy.
33,34,39
 The interesting results coming from some recent but 
not randomized clinical trials, confirm the clinical relevance of achieving a complete molecular 
remission and also pose a challenge to the absolute indication to perform an allogeneic transplant in 
MRD negative patients, as indispensable post-remission therapy.
25,33
 
Despite the evident advantage of being molecularly negative before transplant, our data 
confirm that HSCT is able to convert a significant number of patient (60% of cases) who are MRD 
positive at time of conditioning. Moreover, the subgroup of patients with MRD-negative both at 
HSCT and at 3rd month after HSCT had a better outcome with a 5 year OS of 70%. Conversely, the 
presence, at conditioning, of a documented active disease (relapsed or refractory) was associated 
with a very dismal outcome with a median OS and PFS of 7 and 5 months, respectively. This 
observation clearly points out that Ph+ALL patients with refractory disease should be offered new 
experimental treatments able to induce at least a hematologic response before being considered 
eligible to transplant.
25-31
  
Despite some progress, the NRM, even if reduced, remains a major problem (20% in this recent 
cohort) affecting the decision to advise an allogeneic HSCT to these patients.
14,19
 A transplant from 
a mismatched donor remains significantly associated to a higher risk of NRM most likely as a 
consequence of more GvHD. In this study a large proportion of patients (49%) did not receive an in 
vivo T cell depletion and we observed a relatively high incidence of extensive chronic GvHD (5 
yrs-cumulative incidence of 19%) and this should be carefully considered when planning future 
clinical trials with specific GvHD prophylaxis.
40
 Moreover, the deep molecular remission 
achievable in a proportion of patients before transplant strongly suggest to consider reduced 
intensity conditioning regimens in Ph+ALL, particularly when MRD negative and older than 50 
years. In this setting, preliminary uncontrolled studies suggest that RIC regimens may represent a 
good alternative to myeloablative conditioning (MAC) regimen.
35,41
  
Another controversial issue is the use of TKIs in the post-transplant period to prevent the 
risk of relapse. In this study, treatment with TKIs after HSCT was performed in 40% of patients, in 
most cases as a pre-emptive treatment. As expected, outside the setting of a prospective clinical 
trial, there was a significant lack of uniformity as to the criteria of when and how to start treatment 
with TKIs after transplant. It is extremely important that, quite recently, the EBMT Acute Leukemia 
Working Party published a position paper about the use of post-transplant TKIs.
42
 These 
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recommendations clearly underline the need that the MRD assessments have to become a standard 
part of disease monitoring post HSCT, in order to offer a timely initiation of an effective treatment 
with TKIs to minimize the risk of leukemia relapse.
39,42-44 
Additional limitations of the current study need to be considered, including the 
heterogeneity of TKIs-based programs (with or without chemotherapy) used to achieve remission 
before transplant, the type of conditioning regimens and GvHD prophylaxis. All of these limitations 
preclude any definitive conclusions regarding the optimal standard of care in this context. In 
addition, our registry data base did not contain specific information about BCR/ABL mutations, 
such as the T315I and others, and TKIs related complications.  
In conclusion, our data confirm that alloHSCT is a potentially curative treatment for 
Ph+ALL patients with an excellent outcome for those obtaining a molecular remission before 
transplant. Innovative treatment approaches with targeted molecules will be crucial to further 
improve this scenario, reducing the risk of relapse after transplantation and NRM. In addition, 
prophylactic or preemptive post-transplant therapy with TKIs should be adopted to minimize the 
risk of leukemia relapse. Future prospective clinical trials comparing post-remission strategy with 
or without HSCT are urgently need to define the best evidence-based consolidation among  
Ph+ALL patients achieving molecular remission through the incorporation of innovative drugs into 
frontline treatment. For the present, waiting for new and consolidated data, we suggest to offer 
HSCT for all suitable patients with Ph+ALL in first CR, taking into consideration also patients’ 
preference. 
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                  TABLE 1. Patients and Ph+ALL characteristics (n 441).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics All  evaluable cases 
Age at diagnosis 43 (16-68) 
Gender (M/F) 230/211 
Ph+ALL Mature phenotype 39/397 (9.8%) 
Additional Cytogenetic Abnormalities 124/416 (30%) 
BCR-ABL Transcript type  
p190 289/437 (66%) 
p210 104/437 (24%) 
p190+p210 30/437 (7%) 
WBC at diagnosis (average) [x10^9/L] 59,1 (0,2-451) 
WBC at diagnosis (median) [x10^9/L] 23,9 
WBC > 30 [x10^9/L] 160/374 (43%) 
WBC > 100 [x10^9/L] 62/374 (17%) 
Number of TKI lines (average) 1,3 (1-3) 
Number of TKI lines (median) 1,0 
Time from diagnosis to SCT (median) 7,67 (2,3–78,8) 
Ph+ALL STATUS at SCT  
CR 
1° CR 
CR >1° 
404/441 (92%) 
337/404 (83%) 
67/404 (17%) 
REL/REF 37/441 (8%) 
MRD STATUS at SCT  
CR, MRD-positive 
CR, MRD-negative 
257/404 (64%) 
147/404 (36%) 
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TABLE 2. HSCT characteristics. 
 
 
All (441 pts) 
     Median age (range) at transplant 44 (18-70) 
Donor type:  
Sibling HLA id 159/441 (36%) 
MUD 201/441 (46%) 
Haplo 68/441 (15%) 
Cord Blood 13/441 (3%) 
Source of Stem Cells:  
BM 117/441 (27%) 
PB 311/441 (70%) 
CB 13/441 (3%) 
Conditioning regimen:  
MAC 362/441 (82%) 
RIC 79/441 (18%) 
TBI based 221/441 (50%) 
GVHD prophylaxis  
ATG 226/441 (51%) 
CNI+ MTX/MMF 352/441 (80%) 
Use of PT-CY 23/441 (5%) 
Other 66/441 (15%) 
HCT–CI (available in 402 pt)  
0-2 382/402 (95%) 
>3 20/402 (5%) 
GVHD  
aGVHD requiring therapy (grade > 1) 181/441 (41%) 
cGVHD requiring therapy (limited or extensive) 127/441 (29%) 
 
CNI: calcineurin inhibitors; MTX: methotrexate, MMF:mofetil mycophenolate;  
PT-CY: post-transplant  cyclophosphamide 
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TABLE 3. Univariate analysis of predictors for Overall Survival, Progression-Free Survival, Incidence of Relapse,  Non-Relapse Mortality and Chronic 
Extensive  GVHD. 
  
OS OS PFS PFS NRM NRM RI RI EcGVHD EcGVHD 
Variable Comparison HR (95%CI) p-value HR (95%CI) p-value SHR (95%CI) p-value SHR (95%CI) p-value SHR (95%CI) p-value 
Age per 10 y more 1.13 (1.01 - 1.28) 0.037 1.09 (0.97 - 1.21) 0.143 1.36 (1.13 - 1.62) 0.001 0.88 (0.76 - 1.01) 0.074 1.1 (0.92 - 1.31) 0.291 
Male recipient Yes vs no 1.16 (0.88 - 1.54) 0.297 1.22 (0.94 - 1.58) 0.131 1.41 (0.95 – 2.1) 0.089 1.03 (0.73 - 1.45) 0.877 0.98 (0.63 - 1.51) 0.922 
WBC at diagnosis [x109/L] > 30 vs < 30 1.24 (0.91 - 1.69) 0.18 1.11 (0.83 - 1.49) 0.473 1.02 (0.66 - 1.58) 0.93 1.14 (0.77 - 1.67) 0.51 1 (0.63 - 1.59) 0.996 
Additional karyotypic 
abnormalities 
Yes vs no 1.05 (0.77 - 1.43) 0.77 1.05 (0.78 - 1.4) 0.754 0.94 (0.6 - 1.47) 0.771 1.09 (0.74 - 1.61) 0.657 1.06 (0.67 - 1.7) 0.795 
Transplant year each year later 0.96 (0.92 - 1.01) 0.119 0.97 (0.93 - 1.01) 0.178 0.98 (0.92 - 1.04) 0.525 0.96 (0.91 - 1.02) 0.177 0.95 (0.89 - 1.01) 0.129 
Pre transplant therapy TKI + CHT vs TKI + steroide 0.8 (0.58 - 1.11) 0.177 0.78 (0.58 - 1.05) 0.106 0.86 (0.54 - 1.35) 0.51 0.81 (0.55 - 1.19) 0.283 1.46 (0.82 - 2.61) 0.202 
Interval diagnosis to CR1 > median vs < median 1.51 (1.14 - 2) 0.005 1.54 (1.18 - 2) 0.001 1.36 (0.92 - 2.03) 0.127 1.42 (1 - 2) 0.047 0.75 (0.49 - 1.17) 0.207 
Disease status at HSCT CR2+ vs CR1 2 (1.4 - 2.86) p < 0.001 2.03 (1.45 - 2.84) p < 0.001 1 (0.56 - 1.8) 0.988 2.42 (1.58 - 3.71) p < 0.001 0.59 (0.28 - 1.23) 0.159 
 
Adv vs CR1 3.46 (2.28 - 5.27) p < 0.001 3.67 (2.49 - 5.42) p < 0.001 1.54 (0.79 - 3) 0.202 3.31 (1.94 - 5.63) p < 0.001 0.8 (0.35 - 1.84) 0.601 
MRD status at HSCT neg vs pos 0.59 (0.43 - 0.82) 0.002 0.56 (0.42 - 0.76) p < 0.001 0.96 (0.63 - 1.46) 0.849 0.43 (0.28 - 0.65) p < 0.001 1.7 (1.1 - 2.62) 0.018 
HCT-CI HCT-CI ≥ 3 vs < 3 0.83 (0.53 - 1.3) 0.417 0.69 (0.45 - 1.05) 0.082 0.8 (0.43 - 1.5) 0.492 0.69 (0.39 - 1.2) 0.19 0.68 (0.33 - 1.41) 0.305 
KPS at HSCT KPS ≥90% 0.62 (0.45 - 0.85) 0.003 0.76 (0.56 - 1.04) 0.091 0.78 (0.49 - 1.24) 0.295 0.86 (0.56 - 1.32) 0.49 1.08 (0.61 - 1.91) 0.79 
Donor type Sibling vs MUD 0.88 (0.64 - 1.22) 0.444 0.91 (0.67 - 1.22) 0.517 0.59 (0.36 - 0.97) 0.039 1.25 (0.86 - 1.82) 0.25 1.39 (0.88 - 2.2) 0.157 
 
Alternative vs MUD 1.8 (1.26 - 2.57) 0.001 1.67 (1.2 - 2.33) 0.003 1.78 (1.11 - 2.84) 0.017 1.15 (0.71 - 1.87) 0.562 0.54 (0.25 - 1.17) 0.117 
Female donor Yes vs no 0.87 (0.65 - 1.17) 0.363 0.86 (0.66 - 1.12) 0.259 0.89 (0.59 - 1.34) 0.575 0.91 (0.64 - 1.3) 0.609 1.7 (1.1 - 2.63) 0.016 
CMV serostatus D-/R- vs D+/R+ 0.76 (0.45 - 1.29) 0.313 0.88 (0.56 - 1.39) 0.584 0.74 (0.33 - 1.68) 0.478 0.98 (0.57 - 1.69) 0.948 1.1 (0.56 - 2.17) 0.787 
 
D-/R+ vs D+/R+ 1.23 (0.89 - 1.71) 0.204 1.08 (0.79 - 1.47) 0.637 1.64 (1.06 - 2.53) 0.027 0.7 (0.45 - 1.09) 0.112 0.68 (0.38 - 1.21) 0.188 
 
D+/R- vs D+/R+ 0.87 (0.49 - 1.54) 0.629 0.93 (0.55 - 1.57) 0.787 1.08 (0.49 - 2.36) 0.85 0.86 (0.42 - 1.74) 0.666 1.3 (0.62 - 2.72) 0.485 
Conditioning regimen MAC vs RIC 0.83 (0.59 - 1.17) 0.289 0.84 (0.61 - 1.17) 0.305 0.86 (0.53 - 1.4) 0.546 0.86 (0.56 - 1.33) 0.497 0.97 (0.55 - 1.69) 0.91 
Source of HSC BM vs PB 1.04 (0.75 - 1.43) 0.832 1.03 (0.76 - 1.38) 0.867 1.24 (0.8 - 1.94) 0.333 0.83 (0.55 - 1.25) 0.369 0.74 (0.44 - 1.26) 0.267 
 
CB vs PB 1.83 (0.9 - 3.73) 0.098 1.66 (0.85 - 3.24) 0.141 2.11 (0.81 - 5.5) 0.127 0.96 (0.34 - 2.71) 0.943 0.34 (0.05 - 2.33) 0.27 
Use of ATG Yes vs no 0.82 (0.62 - 1.09) 0.177 0.88 (0.68 - 1.15) 0.357 0.78 (0.53 - 1.17) 0.229 1.03 (0.73 - 1.45) 0.878 0.54 (0.34 - 0.85) 0.007 
TBI-containing regimen Yes vs no 0.86 (0.65 - 1.14) 0.305 0.72 (0.55 - 0.94) 0.014 1.16 (0.78 - 1.72) 0.471 0.56 (0.39 - 0.79) 0.001 1.45 (0.93 - 2.26) 0.099 
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TABLE 4. Multivariate Analysis of significant predictors for Overall Survival, Progression-Free Survival, Incidence of Relapse, Non-Relapse Mortality  and  
Chronic Extensive  GVHD. 
 
 Variable Comparison HR (95%CI) p-value 
Overall Survival 
(OS) 
Donor Alternative vs other (Sibling + UD) 1.77 (1.26 - 2.49) 0.001 
Disease status at Allo-SCT CR2+ vs CR1 1.99 (1.39 - 2.87) p < 0.001 
 
Adv vs CR1 2.75 (1.76 - 4.31) p < 0.001 
Age per 10y more 1.17 (1.03 - 1.32) 0.013 
MRD status at Allo-SCT neg vs pos 0.65 (0.46 - 0.91) 0.011 
Pre Allo-SCT strategy TKI + CHT vs TKI + steroids 0.7 (0.5 - 0.97) 0.035 
Transplant year each year later 0.94 (0.9 - 0.98) 0.008 
Progression-free Survival 
(PFS) 
Donor Alternative vs other (Sibling + UD) 1.61 (1.16 - 2.22) 0.004 
Disease status at Allo-SCT CR2+ vs CR1 2.05 (1.46 - 2.89) p < 0.001 
 
Adv vs CR1 2.71 (1.78 - 4.11) p < 0.001 
MRD status at Allo-SCT neg vs pos 0.6 (0.44 - 0.81) 0.001 
Pre Allo-SCT strategy TKI + CHT vs TKI + steroids 0.63 (0.46 - 0.86) 0.003 
Transplant year each year later 0.95 (0.91 - 1) 0.036 
Non-relapse Mortality 
(NRM) 
Donor Sibling vs UD 0.58 (0.35 - 0.94) 0.027 
 
Alternative vs UD 1.74 (1.09 - 2.8) 0.021 
Age per 10y more 1.4 (1.16 - 1.68) p < 0.001 
Male recipient Yes vs no 1.52 (1.01 - 2.28) 0.047 
Relapse incidence 
(RI) 
Disease status at SCT CR2+ vs CR1 2.55 (1.66 - 3.91) p < 0.001 
 
Adv vs CR1 2.38 (1.39 - 4.06) 0.002 
Age per 10y more 0.8 (0.69 - 0.93) 0.003 
MRD status at SCT neg vs pos 0.54 (0.35 - 0.85) 0.007 
TBI-containing regimen Yes vs no 0.52 (0.36 - 0.75) 0.001 
Transplant year each year later 0.94 (0.89 - 1) 0.047 
Chronic Extensive GVHD 
(EcGVHD) 
Donor Alternative vs other (Sibling + UD) 0.41 (0.2 - 0.87) 0.019 
Use of ATG Yes vs no 0.56 (0.35 - 0.88) 0.011 
Female donor Yes vs no 1.77 (1.15 - 2.74) 0.01 
MRD status at Allo-SCT neg vs pos 1.74 (1.13 - 2.68) 0.012 
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TABLE 5. Comparison between GITMO study and EBMT/JSHCT studies.  
 
GITMO study 
2018 
EBMT study  
(BRISSOT 2015) 
JSHCT study 
(NISHIWAKI 2016) 
patients number 441 473 432 
Period of time 
Retrospective 
(2005-2016) 
Retrospective 
(2000-2010) 
Retrospective 
(1990-2000) 
Pre-transplant TKI -n°of pts  (%) 441 (100%) 390 (82,5%) 432 (100%) 
Age at HSCT-Median (range) 45 (19-70) 42 (18-70) 43 (16-68) 
Status at HSCT 
CR 92% (1° CR 83%) 
RIC/REL 8% 
1° CR (100%) 1° CR (100%) 
MRD-negative at HSCT 36% 65% 64% 
myeloablative regimen 82% 79% 86% 
Transplants from HLA-id  
sibling donor 
36% 49% 32% 
OS 
5 yrs: 50,3% 
63% MRD- 
47% MRD+ 
5 yrs  
46% 
4 yrs 
67% MRD- 
55% MRD+ 
PFS 
5 yrs: 44% 
57% MRD- 
40% MRD+ 
5 yrs  
38% 
4 yrs 
60% MRD- 
46% MRD+ 
CIR 
5 yrs 
19,5%  MRD- 
35,4%  MRD+ 
5 yrs  
36% 
4 yrs 
19%  MRD- 
29%  MRD+ 
NRM 
5 yrs 
 24% 
5 yrs 
 26% 
4 yrs 
21% MRD- 
25% MRD+ 
Post-transplant TKI - n° of pt (%) 178/441 (40%) 157/319 (49%) 103/425 (24%) 
aGVHD 41% 40% (a 100 gg) 7-9% 
cGVHD 29% 53% (a 5 aa) 32-33% 
      Impact of MRD negativity Favorable on OS, PFS, CIR 
No impact on OS, PFS, 
CIR 
Favorable on OS, PFS, CIR 
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FIGURE 1. A: Overall Survival, from transplant,  of the whole transplanted population (median OS= 62 months). B: Progression Free Survival, from 
transplant,  of the whole transplanted population (median PFS= 26 months). C: OS according to status at Allo-SCT (1.MRD neg; 2. Cytologic CR; 3 Refractory 
or Relapsed)-MRD neg vs MRD pos, P= 0,0015. D: PFS, from transplant,   according to status at Allo-SCT (1.MRD neg; 2. Cytologic CR; 3 Refractory or 
Relapsed)-MRD neg vs MRD pos, P=0,003. 
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FIGURE 2. [A] Cumulative Incidence of Relapse at 2 and 5 yrs. 27,9% (95% CI:23,6-32,3) and 31,8% (95%CI:27,1-36,5). [B] CIR according to MRD 
status at SCT. Gray test: SHR= 0.47 (0.31–0.73), p=0,001; CI at 1,2,5 years for MRD neg: 9.1% (5.1%-14.5%), 16.3% (10.6%-23.1%), 19.5% (13%-27%); 
CI at 1,2,5 years for MRD pos: 24.3% (19.2%-29.8%), 30.3% (24.6%-36.2%), 35.4% (29.1%-41.7%). [C] NRM at 1,2,3,5 years: 19.1% (15.5%-22.9%), 
20.7% (17%-24.7%), 24.1% (20%-28.5%), 24.1% (20%-28.5%). [D] Cumulative Incidence of extensive cGVHD at 1,2,3,5 years: 16% (12.7%-19.6%), 
18.5% (14.9%-22.4%), 18.8% (15.2%-22.7%), 19.8% (16%-23.9%) 
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SUPPLEMENTAL FIGURE 1. OS and PFS in MRD NEG patients at 3rd month after Allo-SCT according to MRD Status pre Allo-SCT (group 1. MRD neg 
at Allo-SCT and MRD neg at 3rd month after Allo-SCT; group 2. MRD pos at Allo-SCT and MRD neg at 3rd month after Allo-SCT; group 3. Active disease at 
Allo-SCT  and MRD neg at at 3rd month after Allo-SCT). OS at 5 years: group 1=70% , group 2=53%, group 3=39%. PFS at 5 years: group 1=62% , group 
2=45%, group 3=26%. 
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          SUPPLEMENTAL TABLE 1. MRD Negativity at 3rd month post Allo-SCT according to MRD status pre Allo-SCT. 
 
Pre SCT MRD Status  
N° of MRD-
negative at  3rd 
month post SCT 
OS at 2, 3, 5 yrs PFS a 2, 3 e 5 yrs 
MRD-negative = 147 125/140 (89%) 
125 MRD-negative at SCT 
and at 3rd month: 
72%, 70%, 70% 
125 MRD-negative at SCT 
and at 3rd month: 
66%, 64%, 62% 
MRD-positive = 257 160/246 (65%) 
160 MRD-negative at 3rd 
month: 
67%, 54%, 53% 
160 MRD-negative at  
3rd month: 
56%, 45%, 45% 
Refractory/Relapse = 37 17/35 (49%) 
17 MRD-negative at 3rd 
month: 
39%, 39%, 39% 
17 MRD-negative at  
3rd month: 
26%, 26%, 26% 
Total cases = 441 302/421 (72%) 
302 MRD-negative at 3rd 
month: 
67%, 60%, 60% 
302 MRD-negative at  
3rd month: 
59%, 52%, 52% 
 
 
